Abstract: A method of making N-(2,4-dinitrophenyl)-4-nitrobenzamide from a mixture of 2,4-dinitroaniline, 4-nitrobenzoyl chloride, and solid acid catalyst in an organic solvent, wherein the solid acid catalyst is not soluble in the organic solvent, the solid acid catalyst being an acidic clay, an ion exchange resin, a beta zeolite, a sulfonated tetrafluoroethylene-based fluoropolymer-copolymer, or some mixture of these.

Abstract: This application relates to pharmaceutical engineering, and more particularly to a continuous-flow preparation method of diclofenac sodium. The continuous-flow preparation method includes: subjecting aniline and chloroacetic acid to amidation to obtain 2-chloro-N-phenylacetamide (3); subjecting 2-chloro-N-phenylacetamide (3) and 2,6-dichlorophenol to continuous condensation to obtain N-(2,6-dichlorophenyl)-2-hydroxy-N-phenylacetamide (5); subjecting N-(2,6-dichlorophenyl)-2-hydroxy-N-phenylacetamide (5) and thionyl chloride to chlorination to obtain N-(2,6-dichlorophenyl)-2-chloro-N-phenylacetamide (6); subjecting N-(2,6-dichlorophenyl)-2-chloro-N-phenylacetamide (6) to Friedel-Crafts alkylation in the presence of aluminum chloride to obtain 1-(2,6-dichlorophenyl)-1,3-dihydro-2H-indol-2-one (7); and subjecting 1-(2,6-dichlorophenyl)-1,3-dihydro-2H-indol-2-one (7) to hydrolysis to obtain the diclofenac sodium.

Abstract: Provided are a quaternary ammonium salt and a preparation method and use thereof as an inhibitor, and a water-based drilling fluid and use thereof. The quaternary ammonium salt has a structure shown in formula I, wherein, in the formula I, R1 is selected from the group consisting of —H and —COOH; R2 is selected from the group consisting of —H and —CH2—COOH; R3 is selected from the group consisting of —NH—CH2—CH2—CH2—NH2, —NH—CH2—CH2—NH2, —NH—CH2—CH2—OH, —O—CH2—CH2—NH2, —N—(CH2—CH2—OH)2, and —O—CH2—CH2—NH—CH2—CH2—OH; and n and m are independently 10 to 15.

Abstract: The present disclosure relates to the field of biotechnology. In particular, provided are a ligase fusion protein and an immobilized ligase comprising the same. Also provided is use of the ligase fusion protein or the immobilized ligase in the preparation of conjugates. Further provided is a process for the preparation of conjugates using a ligase or a ligase unit.

Abstract: The compounds of the present invention are represented by the following compounds having Formula I and Formula (I?): where the substituents R1, R2, R2?, R3, R4, R5, R?, R?, X, Y, and Z are as defined herein and where the substituents R1, R2, R3, R4, R5, R?, R?, X, Y, and Z are as defined herein. These compounds are used in the treatment of bacterial infections, parasite infections, fungal infections, cancer, immunologic disorders, autoimmune disorders, neurodegenerative diseases and disorders, inflammatory disorders, or muscular dystrophy or for providing immunosuppression for transplanted organs or tissues.

Abstract: Novel 85Rb-enriched rubidium salt compounds of general formula 1, below and novel compounds of general formula 2, below. Compositions that contain at least one of the novel compounds and optionally further contain an antitumor drug. Methods that entail administering such compounds and compositions to treat cancer, optionally in combination with a conventional form of cancer therapy, such as chemotherapy and radiation treatment. When administered with a conventional form of cancer therapy, the compounds and compositions of the invention may be administered before, simultaneously with, or after administration of the conventional form of cancer therapy.

Abstract: Methods for preparing and using collagen extracts and collagen scaffolds are provided. Additionally, methods and related kits for the repair of articular tissue using the collagen material are provided.

Abstract: Disclosed are peptides that induce an active plant response, but not a hypersensitive response, when applied to plant tissue. These peptides also preferably exhibit improved solubility, stability, resistance to chemical degradation, or a combination of these properties. Use of these peptides or fusion polypeptides, or DNA constructs encoding the same, for modulating plant biochemical signaling, imparting disease resistance to plants, enhancing plant growth, imparting tolerance to biotic stress, imparting tolerance and resistance to abiotic stress, imparting desiccation resistance to cuttings removed from ornamental plants, imparting post-harvest disease or post-harvest desiccation resistance to a fruit or vegetable, or enhancing the longevity of fruit or vegetable ripeness are also disclosed.

Abstract: Provided is a boron-containing compound suitable for the material of a blue light-emitting diode and an organic light-emitting diode using the same. The boron-containing compound has a structure represented by the formula (1): X is each independently —NR1—, —CR2R3—, —O— or —S—. In the —NR1— and —CR2R3—, R1 to R3 are each independently hydrogen, deuterium, an alkyl group having 1 to 6 carbon atoms or an aryl group having 5 to 30 core atoms, and R2 and R3 may connect with each other to form a ring. Cy1 is an aryl group having 5 to 30 core atoms. All or part of hydrogen atoms in the formula (1) may be substituted by deuterium, a halogen, an alkyl group having 1 to 6 carbon atoms, an aryl group having 5 to 30 core atoms, a substituted or unsubstituted silyl group, a substituted or unsubstituted amino group, or cyano group.

Abstract: ABSTRACT: A formulation of Collagen peptides with enzyme inhibitors and hyaluronic acid would increase the levels of collagen and elastin and hyaluronic acid for a long period of time, and would decrease the rate of aging, and age-related changes in the skin and other organs. During aging, the levels of these molecules decrease because of enhanced activities of their respective enzymes. Current approach has utilized collagen peptides alone to increase the levels of collagen and elastin in order to maintain healthy skin. In the absence of inhibitors of enzymes collagenase and elastase, and hyaluronic acid, the levels of collagen peptides, elastin, and hyaluronic acid would decrease. Consequently, the beneficial effects of collagen peptides alone would be reduced within a short period of time.

Abstract: The present invention generally relates to processes for the catalytic hydrogenation of halonitroaromatics. In particular, the present invention includes processes for the catalytic hydrogenation of halonitroaromatics such as 2,5-dicloronitrobenzene to 2,5-dichloroaniline over a platinum-containing catalyst. The present invention also relates to processes for producing 3,6-dichloro-2-methoxybenzoic acid.

Abstract: Disclosed are hypersensitive-response eliciting peptides that exhibit improved solubility, stability, resistance to chemical degradation, or a combination of these properties. Use of these peptides or fusion polypeptides, or DNA constructs encoding the same, for modulating plant biochemical signaling, imparting disease resistance to plants, enhancing plant growth, imparting tolerance to biotic stress, imparting tolerance and resistance to abiotic stress, imparting desiccation resistance to cuttings removed from ornamental plants, imparting post-harvest disease or post-harvest desiccation resistance to a fruit or vegetable, or enhancing the longevity of fruit or vegetable ripeness are also disclosed.

Abstract: The present invention relates to a method of separating amino acids from an aqueous solution comprising amino acids as well as proteins and/or protein decomposition products by combining phosphoric acid with the aqueous solution to precipitate an amino acid monophosphate. The precipitate so formed may be separated from the aqueous solution and used as such, e.g. in plant fertilizer compositions. The precipitate may be redissolved in a suitable liquid, after which phosphate and amino acid may be separated following conventional methods. In either case, the present invention enables highly selective precipitation of arginine and/or lysine monophosphate as crystals.

Abstract: Disclosed are compounds that can penetrate the mitochondrial membrane and that are able to deliver cargo (e.g., therapeutic agents) specifically to the mitochondria.

Abstract: Methods are disclosed including methods for crystallizing a material such as a drug. An example method may include combining a nucleation initiator, a surfactant solution, and an amorphous form of a drug to form a drug precursor dispersion/suspension. The method may also include incubating the drug precursor dispersion/suspension to allow the drug to convert from the amorphous form to a crystalline form.

Abstract: The present disclosure relates to compositions of insulin-Fc fusion proteins and their use to treat feline diabetes.

Abstract: Disclosed are a peptide compound and an application thereof, and a composition containing the peptide compound. The present invention provides a peptide compound represented by compound 3, and a pharmaceutically acceptable salt, a tautomer, a solvate, a crystal form or a prodrug thereof. The compound has good stability and good activity for Kiss1R.

Abstract: The invention provides novel compounds, in particular peptide and peptide analogs, which exhibit functionalities useful for treating a variety of diseases and conditions, particularly diseases and conditions relating to diabetes. The compounds of the invention are also useful for treating impaired pancreatic function, treating metabolic diseases, ex vivo islet induction, expansion and proliferation for transplantation, increasing the survival of transplanted islets in vivo, promoting neuroprotection or nerve regeneration, promoting liver regeneration, and inhibiting inflammation.

Abstract: The invention relates to protein ligation technologies, purified or recombinant peptides, methods for making peptides and proteins with covalent bonds including reversible covalent bonds such as reversible intermolecular covalent bonds, and uses thereof. In particular, this invention relates to intermolecular ester bonds, particularly reversible ester bonds between the hydroxyl and amide groups of amino acid side chains present in recombinant chimeric peptides and proteins and the use of such peptides and proteins in protein engineering, for example in the preparation of multimeric protein complexes, including functionalised multimeric protein complexes.

Abstract: Methods of producing a peptide containing an N-substituted amino acid or N-substituted amino acid analog of the present invention include the steps of: preparing an Fmoc-protected amino acid, an Fmoc-protected amino acid analog, or an Fmoc-protected peptide; deprotecting a protecting group which have an Fmoc skeleton of the Fmoc-protected amino acid and such by using a base; and forming an amide bond by adding a new Fmoc-protected amino acid and such; and when the peptide is produced by a solid-phase method, the obtained peptide is cleaved off from the solid phase under conditions of weaker acidity than TFA. Furthermore, at least one side chain of the obtained peptide has a protecting group that is not deprotected under basic conditions and is deprotected under conditions of weaker acidity than TFA.